Morning Movers 2/24: Rambus (RMBS) Jumps On Ruling; MAP Pharma (MAPP) Slammed On Drug Results
Tweet Send to a Friend
StreetInsider.com Morning Movers:
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) 75% LOWER; Phase 3 Study of Budesonide in Children With Asthma Doesn't ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) 75% LOWER; Phase 3 Study of Budesonide in Children With Asthma Doesn't ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
